ClinicalTrials.gg
CompletedNCT03339219Updated Sep 20, 2021Results posted

A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma

A Phase 2 interventional study of Cabozantinib in Advanced Renal Cell Carcinoma, sponsored by Takeda. Completed at 19 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-09-20.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 42 studies testing cabozantinib in Carcinoma, Renal Cell — 11 open to participants now, 23 under way, 4 of them phase 3. cabozantinib · Carcinoma, Renal Cell.

Enrollment
25th of 42
35 · median 44
Started
2017
with 4 others
Phase 2
25 of 42
6 open now
Registered
11th of 42
by date

Among the 42 studies testing cabozantinib in Carcinoma, Renal Cell, this one is the 25th largest by enrollment, is one of 5 that started in 2017, is one of 25 in phase 2, and was the 11th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

11 of the 42 studies testing cabozantinib in Carcinoma, Renal Cell are open now, in 6 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About cabozantinib

cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing cabozantinib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of cabozantinib measured by Independent Radiology Committee (IRC)-assessed objective response rate (ORR) in Japanese participants with advanced renal cell carcinoma (RCC) that has progressed after prior vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) therapy.

Read the detailed description

The drug being tested in this study is called cabozantinib. Cabozantinib is being tested to treat people who have advanced renal cell carcinoma. This study will look at the efficacy of cabozantinib.

The study will enroll approximately 35 patients. Participants will be enrolled in one treatment group in non-randomized and opened manner:

  • Cabozantinib 60 mg

All participants will be asked to take tablets of cabozantinib at once daily in the fasted state throughout the study.

This multi-center trial will be conducted in Japan. The overall time to participate in this study is approximately at most 3 years. Participants will make multiple visits to the clinic in treatment period, and posttreatment period including a follow-up assessment after last dose of study drug.

03

Conditions studied

  • Advanced Renal Cell Carcinoma

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female Japanese participants 20 years of age or older on the day of consent.
  • Documented histological or cytological diagnosis of renal cell carcinoma (RCC) with a clear-cell component.
  • per 1.1 as determined by the investigator.
  • Must have received at least one VEGFR-targeting TKI (eg, sorafenib, sunitinib, axitinib, pazopanib or tivozanib).
  • For the most recently received VEGFR-targeting TKI the following criteria must apply:

    • Must have radiographically progressed during treatment, or been treated for at least 4 weeks and radiographically progressed within 6 months after the last dose.

Radiographic progression is defined as unequivocal progression of existing tumor lesions or developing new tumor lesions as assessed by the investigator on computerized tomography (CT) or magnetic resonance imaging (MRI) scans.

  • The last dose must have been within 6 months before the first day of study drug administration (Week 1 Day 1).
  • Recovery to baseline or ≤Grade 1 (CTCAE) Version 4.03 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
  • Performance Status (KPS) score of ≥70%.
  • Adequate organ and marrow function at Screening.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with everolimus, or any other specific or selective target of rapamycin complex 1/phosphoinositide 3-kinase/AKT inhibitor (eg, temsirolimus), or cabozantinib.
  • Receipt of any type of small-molecule kinase inhibitor (including kinase inhibitor) within 14 days before Week 1 Day 1.
  • Receipt of any type of anticancer antibody (including investigational antibody) within 28 days before Week 1 Day 1.
  • Radiation therapy for bone within 14 days, and/or any other external radiation therapy within 28 days before Week 1 Day 1. Systemic treatment with radionuclides within 42 days before Week 1 Day 1.

Participants with ongoing complications from prior radiation therapy are not eligible.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Cabozantinib 60 mg

    Cabozantinib 60 mg, tablet, orally, once daily (QD) in the fasted state until unacceptable toxicity or need for subsequent systemic anticancer treatment up to 2.5 years.

    Drug: Cabozantinib

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants whose best overall response was complete response (CR) or partial response (PR) evaluated by the independent review committee (IRC) per response evaluation criteria in solid tumors version 1.1 (RECIST V1.1) which was confirmed by a subsequent evaluation conducted ≥28 days later. Per RECIST V1.1, CR was defined as the disappearance of all lesions, and all pathological lymph nodes (whether target or nontarget) must have a reduction in short axis to \<10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of diameter (SoD) of target lesions, taking as a reference the Baseline SoD.

    Time frame: From first dose of study drug up to first documentation of CR or PR (up to 2.5 years)

Secondary outcomes

  1. Clinical Benefit Rate (CBR)

    CBR was defined as percentage of participants whose best overall response is CR, PR, or stable disease (SD) per RECIST V1.1. Response and progression were evaluated by IRC per RECIST V1.1. CR and PR required confirmation by a subsequent evaluation conducted ≥28 days later and an assessment of SD was made at least 8 weeks after the first day of study drug. Per RECIST V1.1, CR was defined as the disappearance of all lesions, and all pathological lymph nodes (whether target or nontarget) must have a reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in SoD of target lesions, taking as a reference the Baseline SoD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Time frame: From first dose of study drug up to first documentation of CR or PR or SD (up to 2.5 years)

  2. Progression-Free Survival (PFS)

    PFS was defined as the time from the first day of study drug administration to the earlier of progressive disease (PD) per RECIST V1.1 or death due to any cause. Per RECIST V1.1, PD was defined at least a 20% increase in the SoD of target lesions, taking as a reference the smallest (nadir) SoD since (and including) Baseline. In addition to the relative increase of 20%, the SoD also demonstrated an absolute increase of at least 5 mm.

    Time frame: From first dose of study drug up to disease progression or death (up to 2.5 years)

  3. Overall Survival (OS)

    OS is defined as the time from the first day of study drug administration to death due to any cause.

    Time frame: From first dose of study drug up to death due to any cause (up to 2.5 years)

  4. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs whose date of onset occurs on or after the start of study drug and within 30 days after the last dose of study treatment.

    Time frame: From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)

  5. Percentage of Participants With Grade 3 or Higher TEAEs

    An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs whose date of onset occurs on or after the start of study drug and within 30 days after the last dose of study treatment. Severity grade was defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. As per the NCI-CTCAE, Grade 1 scales as mild; Grade 2 scales as moderate; Grade 3 scales as severe or medically significant but not immediately life-threatening; Grade 4 scales as life-threatening consequences; and Grade 5 scales as death related to AE.

    Time frame: From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)

  6. Percentage of Participants With Serious TEAEs

    A serious TEAE was any untoward medical occurrence or effect that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was medically important due to other reasons than the above-mentioned criteria. TEAEs were defined as AEs whose date of onset occurs on or after the start of study drug and within 30 days after the last dose of study treatment.

    Time frame: From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)

  7. Percentage of Participants With TEAEs Leading to Permanent Treatment Discontinuation

    An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs whose date of onset occurs on or after the start of study drug and within 30 days after the last dose of study treatment.

    Time frame: From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)

  8. Percentage of Participants With TEAEs Leading to Dose Modification (Dose Reduction or Interruption)

    An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs whose date of onset occurs on or after the start of study drug and within 30 days after the last dose of study treatment.

    Time frame: From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)

  9. Percentage of Participants With Clinically Significant Abnormal Laboratory Values

    Clinical laboratory tests included tests of serum chemistry, hematology, urine chemistry, coagulation, and thyroid function prespecified in the protocol. Only those categories are reported which are considered clinically significant abnormal laboratory values post baseline, as assessed by the investigator.

    Time frame: From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)

  10. Percentage of Participants With Clinically Significant Abnormal Vital Sign

    Vital signs included diastolic blood pressure (DBP) and systolic blood pressure (SBP) in the sitting position, pulse rate respiratory rate temperature, and weight. Abnormal vital sign values considered by the investigator to be clinically significant are reported as categories.

    Time frame: From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)

07

Results

Posted Sep 20, 2021

Participant flow

Participants took part in the study at 16 investigative sites in Japan from 13 December 2017 to 25 August 2020.

Participant flow — Overall Study
MilestoneCabozantinib 60 mg
Started35
Completed0
Not completed35
Withdrew: Death12
Withdrew: Site terminated by sponsor22
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants whose best overall response was complete response (CR) or partial response (PR) evaluated by the independent review committee (IRC) per response evaluation criteria in solid tumors version 1.1 (RECIST V1.1) which was confirmed by a subsequent evaluation conducted ≥28 days later. Per RECIST V1.1, CR was defined as the disappearance of all lesions, and all pathological lymph nodes (whether target or nontarget) must have a reduction in short axis to \<10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of diameter (SoD) of target lesions, taking as a reference the Baseline SoD.

Time frame:
From first dose of study drug up to first documentation of CR or PR (up to 2.5 years)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsCabozantinib 60 mg
Objective Response Rate (ORR)25.7 (14.122 to 40.582)
SecondaryClinical Benefit Rate (CBR)

CBR was defined as percentage of participants whose best overall response is CR, PR, or stable disease (SD) per RECIST V1.1. Response and progression were evaluated by IRC per RECIST V1.1. CR and PR required confirmation by a subsequent evaluation conducted ≥28 days later and an assessment of SD was made at least 8 weeks after the first day of study drug. Per RECIST V1.1, CR was defined as the disappearance of all lesions, and all pathological lymph nodes (whether target or nontarget) must have a reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in SoD of target lesions, taking as a reference the Baseline SoD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:
From first dose of study drug up to first documentation of CR or PR or SD (up to 2.5 years)
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR)
percentage of participantsCabozantinib 60 mg
Clinical Benefit Rate (CBR)85.7 (69.743 to 95.194)
SecondaryProgression-Free Survival (PFS)

PFS was defined as the time from the first day of study drug administration to the earlier of progressive disease (PD) per RECIST V1.1 or death due to any cause. Per RECIST V1.1, PD was defined at least a 20% increase in the SoD of target lesions, taking as a reference the smallest (nadir) SoD since (and including) Baseline. In addition to the relative increase of 20%, the SoD also demonstrated an absolute increase of at least 5 mm.

Time frame:
From first dose of study drug up to disease progression or death (up to 2.5 years)
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsCabozantinib 60 mg
Progression-Free Survival (PFS)11.1 (7.4 to 18.4)
SecondaryOverall Survival (OS)

OS is defined as the time from the first day of study drug administration to death due to any cause.

Time frame:
From first dose of study drug up to death due to any cause (up to 2.5 years)
Reported as:
Median · months
Overall Survival (OS)
monthsCabozantinib 60 mg
Overall Survival (OS)NA (23.4 to NA)
SecondaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs whose date of onset occurs on or after the start of study drug and within 30 days after the last dose of study treatment.

Time frame:
From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsCabozantinib 60 mg
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)100.0
SecondaryPercentage of Participants With Grade 3 or Higher TEAEs

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs whose date of onset occurs on or after the start of study drug and within 30 days after the last dose of study treatment. Severity grade was defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. As per the NCI-CTCAE, Grade 1 scales as mild; Grade 2 scales as moderate; Grade 3 scales as severe or medically significant but not immediately life-threatening; Grade 4 scales as life-threatening consequences; and Grade 5 scales as death related to AE.

Time frame:
From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Grade 3 or Higher TEAEs
percentage of participantsCabozantinib 60 mg
Percentage of Participants With Grade 3 or Higher TEAEs82.9
SecondaryPercentage of Participants With Serious TEAEs

A serious TEAE was any untoward medical occurrence or effect that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was medically important due to other reasons than the above-mentioned criteria. TEAEs were defined as AEs whose date of onset occurs on or after the start of study drug and within 30 days after the last dose of study treatment.

Time frame:
From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Serious TEAEs
percentage of participantsCabozantinib 60 mg
Percentage of Participants With Serious TEAEs42.9
SecondaryPercentage of Participants With TEAEs Leading to Permanent Treatment Discontinuation

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs whose date of onset occurs on or after the start of study drug and within 30 days after the last dose of study treatment.

Time frame:
From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)
Reported as:
Number · percentage of participants
Percentage of Participants With TEAEs Leading to Permanent Treatment Discontinuation
percentage of participantsCabozantinib 60 mg
Percentage of Participants With TEAEs Leading to Permanent Treatment Discontinuation17.1
SecondaryPercentage of Participants With TEAEs Leading to Dose Modification (Dose Reduction or Interruption)

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs whose date of onset occurs on or after the start of study drug and within 30 days after the last dose of study treatment.

Time frame:
From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)
Reported as:
Number · percentage of participants
Percentage of Participants With TEAEs Leading to Dose Modification (Dose Reduction or Interruption)
percentage of participantsCabozantinib 60 mg
Dose Reduction88.6
Dose Interruption80.0
SecondaryPercentage of Participants With Clinically Significant Abnormal Laboratory Values

Clinical laboratory tests included tests of serum chemistry, hematology, urine chemistry, coagulation, and thyroid function prespecified in the protocol. Only those categories are reported which are considered clinically significant abnormal laboratory values post baseline, as assessed by the investigator.

Time frame:
From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Significant Abnormal Laboratory Values
percentage of participantsCabozantinib 60 mg
White Blood Cells (WBC) Decreased17.1
Absolute Neutrophil Count (ANC) Decreased5.7
Lymphocytes Increased2.9
Lymphocytes Decreased34.3
Platelets Decreased20.0
Hemoglobin Increased2.9
Hemoglobin Decreased85.7
Albumin Decreased88.6
Alkaline Phosphatase (ALP) Increased65.7
Amylase Increased57.1
Alkaline Phosphatase (ALT) Increased74.3
Aspartate Aminotransferase (AST) Increased80.0
Corrected Calcium Increased5.7
Corrected Calcium Decreased8.6
Creatinine Increased97.1
Gamma-glutamyl Transferase (GGT) Increased54.3
Glucose Increased62.9
Glucose Decreased5.7
Lactate Dehydrogenase (LDH) Increased100
Lipase Increased45.7
Magnesium Increased14.3
Magnesium Decreased77.1
Phosphate Decreased54.3
Potassium Increased14.3
Potassium Decreased22.9
Sodium Decreased48.6
Total Bilirubin Increased17.1
Urine Protein-to-creatinine Ratio (UPCR) Increased91.4
SecondaryPercentage of Participants With Clinically Significant Abnormal Vital Sign

Vital signs included diastolic blood pressure (DBP) and systolic blood pressure (SBP) in the sitting position, pulse rate respiratory rate temperature, and weight. Abnormal vital sign values considered by the investigator to be clinically significant are reported as categories.

Time frame:
From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Significant Abnormal Vital Sign
percentage of participantsCabozantinib 60 mg
BP Increased: SBP <120 millimeters of mercury (mmHg) and DBP <80 mmHg2.9
BP Increased: SBP 120<= - <=139 mmHg or DBP 80<= - <=89 mmHg11.8
BP Increased: SBP 140<= - <=159 mmHg or DBP 90<= - <=99 mmHg64.7
BP Increased: SBP 160 mmHg<= and DBP <120 mmHg, or DBP 100<=- <=119 mmHg20.6
Weight Decreased >=10% from Baseline37.1

Adverse events

Collected over Up to 2.6 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cabozantinib 60 mg12/35 (34.3%)15/35 (42.9%)35/35 (100%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventCabozantinib 60 mg
CholecystitisHepatobiliary disorders2/35
PneumoniaInfections and infestations2/35
Renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/35
IleusGastrointestinal disorders1/35
Jaundice cholestaticHepatobiliary disorders1/35
Lung infectionInfections and infestations1/35
Amylase increasedInvestigations1/35
Lipase increasedInvestigations1/35
Pancreatic enzymes increasedInvestigations1/35
Decreased appetiteMetabolism and nutrition disorders1/35
Most frequent other events
Showing 10 of 75
Most frequent other events
EventCabozantinib 60 mg
DiarrhoeaGastrointestinal disorders24/35
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders23/35
ProteinuriaRenal and urinary disorders17/35
StomatitisGastrointestinal disorders15/35
DysgeusiaNervous system disorders15/35
HypertensionVascular disorders15/35
Weight decreasedInvestigations14/35
Hepatic function abnormalHepatobiliary disorders13/35
MalaiseGeneral disorders11/35
Decreased appetiteMetabolism and nutrition disorders11/35

Baseline characteristics

Full Analysis Set (FAS) included all participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Cabozantinib 60 mg
Mean62.6 ± 9.81
Sex: Female, Male
Sex: Female, Male(Participants)Cabozantinib 60 mg
Female11
Male24
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Cabozantinib 60 mg
Region of Enrollment
Region of Enrollment(Participants)Cabozantinib 60 mg
Japan35
Memorial Sloan-Kettering Cancer Center (MSKCC) Risk Factors
Memorial Sloan-Kettering Cancer Center (MSKCC) Risk Factors(Participants)Cabozantinib 60 mg
Favorable Risk (0)11
Intermediate Risk (1)19
Poor Risk (2 or 3)5
Heng Criteria
Heng Criteria(Participants)Cabozantinib 60 mg
Favorable Risk (0)6
Intermediate Risk (1-2)22
Poor Risk (3-6)7
Karnofsky Performance Status (PS)
Karnofsky Performance Status (PS)(Participants)Cabozantinib 60 mg
70 (Cares for self, unable to carry on normal activity or to do active work)1
80 (Normal activity with effort; some signs or symptoms of disease)5
90 (Able to carry on normal activity; minor signs or symptoms of disease)5
100 (Normal, no complaints, no evidence of disease)24
Eastern Cooperative Oncology (ECOG) Group PS
Eastern Cooperative Oncology (ECOG) Group PS(Participants)Cabozantinib 60 mg
Grade 026
Grade 19
08

Study locations

19 sites
  • Nagoya University Hospital
    Nagoya, Aichi, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaido, Japan
  • Sapporo Medical University Hospital
    Sapporo, Hokkaido, Japan
  • Kobe University Hospital
    Kobe, Hyogo, Japan
  • Yokohama City University Hospital
    Yokohama, Kanagawa, Japan
  • Yokohama City University Medical Center
    Yokohama, Kanagawa, Japan
  • Kindai University Hospital
    Osakasayama, Osaka, Japan
  • Osaka University Hospital
    Suita, Osaka, Japan
  • Nippon Medcal School Hospital
    Bunkyo-ku, Tokyo, Japan
  • Toranomon Hospital
    Minato-ku, Tokyo, Japan
  • Keio University Hospital
    Shinjuku-ku, Tokyo, Japan
  • Tokyo Women's Medical University Hospital
    Shinjuku-ku, Tokyo, Japan
  • Kyushu University Hospital
    Fukuoka, Japan
  • Niigata University Medical and Dental Hospital
    Niigata, Japan
  • Okayama University Hospital
    Okayama, Japan
  • Osaka City University Hospital
    Osaka, Japan
  • Osaka International Cancer Institute
    Osaka, Japan
  • Tokushima University Hospital
    Tokushima, Japan
  • Yamagata University Hospital
    Yamagata, Japan
09

References and documents

Publications

  • Tomita Y, Tatsugami K, Nakaigawa N, Osawa T, Oya M, Kanayama H, Nakayama Kondoh C, Sassa N, Nishimura K, Nozawa M, Masumori N, Miyoshi Y, Kuroda S, Tanaka S, Kimura A, Tamada S. Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients. Int J Urol. 2020 Nov;27(11):952-959. doi: 10.1111/iju.14329. Epub 2020 Aug 12. PubMed 32789967 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Aug 2020, 32 months.

Results were first posted in Sep 2021, 1 year after primary completion.

Of 47 industry-sponsored phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's 32 months is close to that.

Counting every sponsor, half of 230 studies reached it within 58 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2017
First posted
Nov 13, 2017
StartActual
Dec 13, 2017
Primary completionActual
Aug 25, 2020
CompletionActual
Aug 25, 2020
Results first posted
Sep 20, 2021
Last update
Sep 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03339219
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Nov 13, 2017
Start date
Dec 13, 2017
Primary completion
Aug 25, 2020
Completion
Aug 25, 2020
Results posted
Sep 20, 2021
Last update
Sep 20, 2021

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion